We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
Read MoreHide Full Article
Murray Hill, NJ-based C.R. Bard Inc. reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Net sales during the fourth quarter of 2016 increased from $870.8 million on a year-over-year basis to $967.1 million. The figure was also better than the Zacks Consensus Estimate of $956 million.
Stock Performance
Over the last three months, the stock gained 7.75% comparing favorably with the Zacks classified Medical/Dental Supplies sub industry’s gain of 3.98%. Also, a long-term expected earnings growth rate of 11.17% instills confidence in investors.
Net sales in the U.S. were $655.0 million and net sales outside the U.S. were $312.1 million, reflecting an increase of 8% and 18%, respectively, over the prior-year period.
Segment Details
Vascular product sales increased 9% year over year (up 10% at cc) to $262.0 million.
Coming to Urology, sales increased 16% on a year-over-year basis (up 18% at cc) to $253.0 million. Oncology sales were up 9% (up 10% at cc) year over year to $259.4 million.
Surgical Specialties sales were up 9% (up 10% at cc) year over year to $167.2 million.
Sales from the ‘other product line’ increased 11% on a year-over-year basis to almost $25.5 million.
2017 Guidance
For full-year 2017, C.R. Bard projects net sales to increase between 4% and 5% on an as-reported basis. Excluding the impact of foreign exchange, net sales are projected to increase between 6% and 6.5% from the prior year. Earnings per share, after adjusting for amortization of intangibles, are projected between $11.45 and $11.75, representing growth of 11% to 14% year over year.
Zacks Rank & Key Picks
Currently, C.R. Bard carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus Glaukos Corporation (GKOS - Free Report) , Dextera Surgical Inc. and Hologic, Inc. (HOLX - Free Report) . Notably, Addus Glaukos sports a Zacks Rank #1 (Strong Buy) while Dextera and Hologic have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 161.3%.
Dextera Surgical has a long-term expected earnings growth rate of 25. Additionally, the company posted a promising one-month return of almost 57.1%.
Hologic has a long-term expected earnings growth rate of roughly 10.34%. Notably, the stock represents a solid one-year return of 21.47%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
Murray Hill, NJ-based C.R. Bard Inc. reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Net sales during the fourth quarter of 2016 increased from $870.8 million on a year-over-year basis to $967.1 million. The figure was also better than the Zacks Consensus Estimate of $956 million.
Stock Performance
Over the last three months, the stock gained 7.75% comparing favorably with the Zacks classified Medical/Dental Supplies sub industry’s gain of 3.98%. Also, a long-term expected earnings growth rate of 11.17% instills confidence in investors.
C.R. Bard, Inc. Price, Consensus and EPS Surprise
C.R. Bard, Inc. Price, Consensus and EPS Surprise | C.R. Bard, Inc. Quote
Quarter Highlights
Net sales in the U.S. were $655.0 million and net sales outside the U.S. were $312.1 million, reflecting an increase of 8% and 18%, respectively, over the prior-year period.
Segment Details
Vascular product sales increased 9% year over year (up 10% at cc) to $262.0 million.
Coming to Urology, sales increased 16% on a year-over-year basis (up 18% at cc) to $253.0 million.
Oncology sales were up 9% (up 10% at cc) year over year to $259.4 million.
Surgical Specialties sales were up 9% (up 10% at cc) year over year to $167.2 million.
Sales from the ‘other product line’ increased 11% on a year-over-year basis to almost $25.5 million.
2017 Guidance
For full-year 2017, C.R. Bard projects net sales to increase between 4% and 5% on an as-reported basis. Excluding the impact of foreign exchange, net sales are projected to increase between 6% and 6.5% from the prior year. Earnings per share, after adjusting for amortization of intangibles, are projected between $11.45 and $11.75, representing growth of 11% to 14% year over year.
Zacks Rank & Key Picks
Currently, C.R. Bard carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus Glaukos Corporation (GKOS - Free Report) , Dextera Surgical Inc. and Hologic, Inc. (HOLX - Free Report) . Notably, Addus Glaukos sports a Zacks Rank #1 (Strong Buy) while Dextera and Hologic have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 161.3%.
Dextera Surgical has a long-term expected earnings growth rate of 25. Additionally, the company posted a promising one-month return of almost 57.1%.
Hologic has a long-term expected earnings growth rate of roughly 10.34%. Notably, the stock represents a solid one-year return of 21.47%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>